An integrated in vitro and in vivo approach favored by TransBIOTech researchers
Probiotics are currently at the forefront of numerous innovations in human health. Their potential benefits (modulation of inflammation, improved metabolism, or enhanced resilience to infections) are extensively documented in scientific literature. However, transforming these promises into robust evidence remains a significant challenge.
The diversity of bacterial strains, the complexity of the gut microbiota, and the multiplicity of action mechanisms make evaluating probiotic efficacy particularly demanding. In this context, it becomes essential to move beyond marketing claims and rely on rigorous, integrated experimental strategies.
To generate robust and relevant data, TransBIOTech researchers favor an approach combining in vitro and in vivo assays. This complementary strategy allows for deciphering the biological mechanisms of probiotics, identifying the most promising strains, and better predicting their efficacy in various physiological contexts.
1. In Vitro Approaches for Evaluating the Immunomodulatory Properties of Probiotics
Dendritic cells play a central role in intestinal immunity. As true sentinels of the immune system, they capture signals from the intestinal environment and direct the immune response towards either an inflammatory or a tolerant profile. They thus represent a relevant model for studying the immunomodulatory properties of probiotics.
In this type of approach, dendritic cells derived from stable cell lines or differentiated from primary human cells are cultured in vitro and exposed to various probiotic strains. The objective is to evaluate their capacity to induce the maturation and activation of these cells.
Flow cytometry allows for the measurement of surface marker expression associated with the activation and maturation of dendritic cells (CD80, CD86, MHC-II, CD40). Concurrently, the production of pro-inflammatory cytokines (TNF, IL-1β, IL-6) or anti-inflammatory cytokines (IL-10, TGF-β) is quantified in the cell supernatant by ELISA. These assays provide a rapid and comparative evaluation of multiple strains prior to their in vivo validation.
Discover our immunology capabilities.
Discover our microbiology capabilities.
2. In Vivo Approaches for Evaluating the Anti-inflammatory and Metabolic Impact of Probiotics
Murine Models of Inflammatory Bowel Diseases
Chronic inflammation is implicated in numerous pathologies, particularly inflammatory bowel diseases. Probiotics are frequently studied for their ability to strengthen intestinal barrier integrity and modulate an excessive inflammatory response.
Several murine models of ulcerative colitis—induced by chemical agents such as dextran sulfate sodium (DSS), trinitrobenzenesulfonic acid (TNBS), or by immune mechanisms like T-lymphocyte transfer—allow for the reproduction of the main characteristics of human pathophysiology.
In these models, the impact of probiotics is evaluated using the disease activity score, quantification of systemic or local inflammatory markers, and histological analysis of intestinal tissue integrity. These approaches provide an integrated view of anti-inflammatory mechanisms, from the intestinal epithelium to systemic immunity.
Murine Model of Metabolic Syndrome
The potential benefits of probiotics are not limited to their anti-inflammatory properties. Numerous studies also suggest a role in the prevention or improvement of metabolic syndrome, characterized by excessive weight gain, insulin resistance, and dyslipidemia (Wieers et al., 2019).
The high-fat diet-induced murine model of metabolic syndrome is a preferred tool for studying these effects. Probiotics are administered orally over several weeks, with monitoring of body weight and food intake. Insulin resistance is assessed using glucose tolerance tests, while repeated blood samples allow for tracking the lipid profile.
The impact of probiotics on the composition and diversity of the gut microbiota can also be analyzed by sequencing intestinal content. Concurrently, the quantification of metabolic biomarkers such as short-chain fatty acids (SCFAs) provides key information on the functional activity of the microbiota.
Discover our preclinical pharmacology capabilities.
3. Towards Robust and Credible Scientific Demonstration
What This Means for Start-ups and SMEs
Evaluating the efficacy of probiotics cannot be reduced to a single test or an isolated model. An integrated approach, combining relevant in vitro and in vivo assays, not only allows for a better understanding of the specific mechanisms of action of strains but also enables the selection of the most promising candidates from the early stages of development.
For start-ups and SMEs in the biotech, nutraceutical, and foodtech sectors, this strategy represents a key lever:
- reducing scientific risks,
- guiding formulation and positioning choices,
- generating credible data for partners, investors, and funding bodies,
- and strengthening the robustness of claims in an increasingly demanding regulatory environment.
Generating robust evidence is no longer optional; it is an essential condition for transforming an innovation into lasting success.
Author: Carole-Ann Huppé, PhD, MBA, Preclinical Pharmacology Researcher, TransBIOTech
Reference: Wieers, G., et al. (2019). How Probiotics Affect the Microbiota. Frontiers in Cellular and Infection Microbiology, 9, 454
